Alkem Laboratories Ltd

Mid Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Alkem Laboratories Ltd has announced an increase in investment for its greenfield formulations manufacturing facility in Ujjain from ₹533 crore to ₹1,036 crore, approved by the board.

Alkem Labs Doubles Investment for Ujjain Facility - 02 Apr, 2026

Alkem Laboratories Ltd has incorporated a fully owned subsidiary in Dubai Healthcare City, UAE, expanding its international presence and business operations.

Alkem Labs Establishes Subsidiary in Dubai - 30 Mar, 2026

Alkem Laboratories received GMP compliance for its Daman facility and launched Semaglutide injection in India, priced at ₹1,800 for a month, enhancing access to diabetes treatment.

Alkem Launches Semaglutide Injection, Receives GMP Certification - 21 Mar, 2026

Alkem Laboratories has been awarded a GMP Compliance Certificate from the Malta Medicines Authority for its Daman facility, valid for three years. This certification enables the company to manufacture and export pharmaceutical products to EU countries, ensuring compliance with high-quality standards.

Alkem Receives EU GMP Certification for Daman Facility - 20 Mar, 2026

Alkem Laboratories has announced a ₹533 crore investment for a new greenfield formulations manufacturing facility in Ujjain, Madhya Pradesh, acquiring 30 acres of land. This strategic move aims to enhance production capacity and strengthen infrastructure.

Alkem Laboratories Invests in New Ujjain Facility - 18 Mar, 2026

Alkem Laboratories received a GMP certificate from the German health authority for its Baddi manufacturing facility, valid for three years. The inspection showed no major issues.

Alkem Labs Secures GMP Certification for Baddi Facility - 16 Mar, 2026

Alkem Laboratories Ltd's subsidiary has signed a deal to acquire a 51%-55% stake in Occlutech Holding AG, advancing a previously announced agreement.

Alkem Lab's Subsidiary Acquires Stake in Occlutech - 06 Mar, 2026

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Foreign Institutions have increased holdings from 9.48% to 9.97% in Dec 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Up

In the last 3 years, Lupin Ltd has given 245.2% return, outperforming this stock by 191.0%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Against Peers

Promoters holdings remained unchanged at 51.20% of holdings in Dec 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

In the last 1 year, Torrent Pharmaceuticals Ltd has given 23.3% return, outperforming this stock by 11.5%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Retail Investor have decreased holdings from 17.40% to 17.30% in Dec 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Mutual Funds have decreased holdings from 16.94% to 16.06% in Dec 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Down

In the last 7 days, ALKEM stock has moved down by -0.8%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Dip

Netprofit is down for the last 2 quarters, 765.06 Cr → 636.02 Cr (in ₹), with an average decrease of 16.9% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Down

Revenue is down for the last 2 quarters, 4.10K Cr → 3.87K Cr (in ₹), with an average decrease of 5.5% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Fall

Nifty 200

NIFTY PHARMA

S&P BSE 400 MidSmallCap

Nifty Midcap 100

BSE Healthcare

Nifty Midcap 150

Nifty MidSmallcap 400

Nifty Midcap 50

S&P BSE 150 MidCap

BSE 500

Nifty Healthcare

BSE 200

Nifty LargeMidcap 250

S&P BSE 250 LargeMidCap

Nifty 500

HDFC Mid Cap Fund -Direct Plan - Growth Option

SBI Large & Midcap Fund Direct Growth

ICICI Prudential Multi-Asset Fund Direct Plan Growth

Nippon India Growth Mid Cap Fund - Direct Plan - Growth Mid Cap

ICICI Prudential Large & Mid Cap Fund Direct Plan Growth

Alkem Laboratories Ltd’s net profit jumped 1.63% since last year same period to ₹636.02Cr in the Q3 2025-2026. On a quarterly growth basis, Alkem Laboratories Ltd has generated -16.87% fall in its net profits since last 3-months.

Alkem Laboratories Ltd Earnings Results

In the quarter ending December 2025, Alkem Laboratories Ltd has declared dividend of ₹43.00 per share on 13 Feb 2026 - translating a dividend yield of 0.97%.

Name	Value	Action
MACD level (12,26)	0.01	Bearish
CCI (20)	-419.43	Bullish
RSI (14)	44.14	Neutral
Momentum (10)	-11	Bearish
ADI (14)	25.26	Bearish
Ultimate Oscillator (7,14,28)	80.01	Bullish

Name	Value	Action
SMA (20)	5260.2	Bearish
EMA (20)	5256.41	Bearish
VWMA (20)	5257.14	Bearish
SMA (50)	5250.92	Bearish
EMA (50)	5252.2	Bearish
SMA (200)	5217.99	Bullish
EMA (200)	5221.53	Bullish
KAMA (200)	5247.42	Bullish
DEMA (200)	5250.6	Bearish

Alkem Laboratories Ltd (ALKEM)

Summary

Overall

Oscillators

Moving Averages